NCT05435248View on ClinicalTrials.gov

Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

354

Participants

Timeline

Start Date

March 2, 2022

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2026

Conditions
Advanced or Metastatic NSCLC
Interventions
DRUG

HS-10375

HS-10375 will be administered orally once daily in a continuous regimen

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY